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ABSTRACT
From December 2006 to December 2016, 1093 human immunodeficiency virus (HIV) 
individuals < 70 years enrolled in Korea human immunodeficiency virus/acquired immune 
deficiency syndrome (HIV/AIDS) cohort were analyzed to investigate the prevalence of HIV/HBV 
co-infection rate and hepatitis B virus surface antibody (HBsAb) positive rate based on birth 
year. The HBV co-infection prevalence rate was the highest (8.8%) in patients born between 
1960 and 1964 and the lowest (0%) among those born between 1995 and 1999. A decreasing 
linear trend of HBV co-infection rate was observed according to the 5-year interval changes. 
HBsAb-positive rate was only 58.1% in our study. The national HBV vaccination programs 
have effectively lowered the HBV co-infection rate in HIV population. However, it is identified 
that the HIV population has low HBsAb positive rate. Further evidences supporting efficacy 
of booster immunization for HBsAb negative HIV patients are required and efforts should be 
made to increase HBsAb positive rates among HIV patients to prevent horizontal transmission.
Keywords: Hepatitis B Virus; HIV Infection; Co-Infection; Vaccination; National Cohort
Approximately 10% of the population infected with human immunodeficiency virus (HIV) 
has concurrent chronic hepatitis B, with co-infection rates more common in areas of high 
prevalence for both viruses.1,2 Korea was classified as a high hepatitis B virus (HBV) endemic 
area before implementing universal vaccination; in the 1980s, around 11% of neonates 
in Korea were infected with HBV through vertical transmission.3 Efforts to maintain the 
HBV vaccination rate above 95% has resulted in the average prevalence rate of hepatitis B 
decreasing to 3% since 2010. The hepatitis B virus surface antigen (HBsAg) positive rates 
of younger age groups markedly declined to 0.3% in 2016.4 However, there has been no 
further decline ever since and hepatitis B continues to remain a high prevalence disease 
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in Korea. The fact that hepatitis B is still identified with low probability does not preclude 
the possibility of a horizontal transmission. While the prevalence rate of hepatitis B is an 
estimated 5%, as per the Korea HIV/AIDS (acquired immune deficiency syndrome) cohort 
in 2017,5 seroprevalence of HBV among HIV patients has been rarely reported in Korea after 
introduction of HBV vaccination as supplementary immunization activity in 1985 and the 
national vaccination program (NIP) for newborns in 1995.6 Therefore, we aimed to evaluate 
the HBsAg, HBsAb status and the effect of HBV vaccination programs in HIV patients.
The Korea HIV/AIDS cohort is a multicenter, prospective study consisting of 15 university 
hospitals nationwide and funded by the Korean Centers for Disease Control and Prevention 
(KCDC). This cohort has an ongoing enrollment of HIV-infected adult patients older than 18 
years. We analyzed HIV individuals enrolled between December 2006 and December 2016. 
To evaluate the prevalence of HBV co-infection rate and HBsAb status among HIV-infected 
persons, we investigated the presence of HBsAg and HBsAb based on the year of birth.
According to the HIV/AIDS management guidelines of KCDC, HIV infection was screened for 
using enzyme immunoassays (EIA) and confirmed with western blotting. HBV infection was 
defined based on HBsAg positivity with or without protective antibodies. HBsAb positivity 
was confirmed by a positive enzyme linked immunosorbent assay test. The seropositivity of 
HBsAg was determined by cut-off index of HBsAg > 1.0 and HBsAb > 10 mIU/mL.
The statistical analyses are performed with descriptive statistics and linear regression. The 
statistical analyses were performed using R statistics ver. 3.1 (R Foundation for Statistical 
Computing, Vienna, Austria).
A total of 1,093 individuals (mean age, 47 years; interquartile range [IQR], 39–56) were 
included for analysis (Fig. 1). Most participating patients were men (1,028/1,093; 94.15%) and 
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Total number of patients
n = 1,229
1,130 HIV patients remained
99 patients were excluded
because patients were > 70 years old
1,093 participants were included for analysis
37 patients were excluded
because of missing HBsAg and HBsAb data
HIV mono infection
n = 1,036 (94.8%)
HIV/HBV co-infection
n = 57 (5.2%)
HBsAb positive
n = 632 (61.0%)
HBsAb negative
n = 404 (39.0%)
Fig. 1. Profile of enrolled patients. 
HIV = human immunodeficiency virus, HBV = hepatitis B virus, HBsAb = hepatitis B virus surface antibody.
Korean ethnicity (1,079/1,093; 98.7%). The main route of transmission was sexual contact 
accounting for 1058 (96.8%) patients. Further, 127 (11.6%) patients experienced disease 
transmission from foreign countries (Table 1).
The HIV/HBV co-infection rate was identified in 5.2% (57/1,093) and HBV/HCV/HIV co-
infection was only found in one patient born between 1960 and 1964. The HIV/HBV co-
infection incidence was highest (8.8%; 12/174) among patients in the birth years between 
1960 and 1964 and lowest (0%; 0/7) among those born between 1995 and 1999. A decreasing 
linear trend was observed with 5-year intervals (Fig. 2). Before year 1985, the proportion of 
HBsAg positivity was 54 (5.8%), but after 1985, between 1985 and 1995, the HBsAg positivity 
reduced to 3 (2.0%), and no hepatitis B co-infection was identified since 1995.
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Table 1. Patients' baseline characteristics according to birth year
Variables Birth year Total (n = 1,093) P value
Before 1985 (n = 935) 1985–1995 (n = 151) After 1995 (n = 7)
Gender 0.140
Women 61 (6.5) 4 (2.6) 0 (0.0) 65 (5.9)
Men 874 (93.5) 147 (97.4) 7 (100.0) 1,028 (94.1)
Age, yr 50.0 (43.0–57.0) 30.0 (29.0–32.0) 24.0 (23.0–24.0) 47.0 (39.0–56.0) < 0.001
Ethnicity 0.009
Korean 924 (98.8) 149 (98.7) 6 (85.7) 1,079 (98.7)
Othersa 11 (1.2) 2 (1.3) 1 (14.3) 14 (1.3)
Transmission route of HIV 0.723
Sexual contact 905 (96.8) 146 (96.7) 7 (100.0) 1,058 (96.8)
Others 3b (0.3) 2c (1.3) 0 (0.0) 5 (0.5)
Reception of blood/product 2 (0.2) 0 (0.0) 0 (0.0) 2 (0.2)
Unknown 25 (2.7) 3 (2.0) 0 (0.0) 28 (2.6)
Transmitted area 0.107
In Korea 605 (64.7) 95 (62.9) 6 (85.7) 706 (64.6)
Foreign country 115 (12.3) 11 (7.3) 1 (14.3) 127 (11.6)
Unknown 215 (23.0) 45 (29.8) 0 (0.0) 260 (23.8)
Fatty liver 0.528
Yes 18 (1.9) 1 (0.7) 0 (0.0) 19 (1.7)
No 872 (93.3) 146 (96.7) 7 (100.0) 1,025 (93.8)
Unknown 45 (4.8) 4 (2.6) 0 (0.0) 49 (4.5)
Liver cirrhosis 0.539
Yes 7 (0.7) 0 (0.0) 0 (0.0) 7 (0.6)
No 882 (94.3) 147 (97.4) 7 (100.0) 1,036 (94.8)
Unknown 46 (4.9) 4 (2.6) 0 (0.0) 50 (4.6)
Hepatocellular carcinoma 0.416
No 890 (95.2) 147 (97.4) 7 (100.0) 1,044 (95.5)
Unknown 45 (4.8) 4 (2.60) 0 (0.0) 49 (4.5)
Hepatitis B vaccination history 0.033
Yes 283 (30.3) 63 (41.7) 3 (42.9) 349 (31.9)
No 389 (41.6) 53 (35.1) 4 (57.1) 446 (40.8)
Unknown 263 (28.1) 35 (23.2) 0 (0.0) 298 (27.3)
HBsAg 0.125
Positive 54 (5.8) 3 (2.0) 0 (0.0) 57 (5.2)
Negative 881 (94.2) 148 (98.0) 7 (100.0) 1,036 (94.8)
HBsAb 0.161
Positive 539 (57.6) 94 (62.3) 2 (28.6) 635 (58.1)
Negative 396 (42.4) 57 (37.7) 5 (71.4) 458 (41.9)
HCV 0.905
Positive 21 (2.2) 3 (2.0) 0 (0.0) 24 (2.2)
Negative 914 (97.8) 148 (98.0) 7 (100.0) 1,069 (97.8)
Values are presented as medians (interquartile range) or number (%).
HIV = human immunodeficiency virus, HBsAg = hepatitis B virus surface antibody, HCV = hepatitis C virus.
aOthers denote non-Korean Asian patients; b1 acupuncture, 1 needle stick injury, 1 intravenous drug injection; c1 tattoo, 1 intravenous drug injection.
The HBsAb positive rate was 58.1% (635/1,093) in the total HIV population (Table 1). The 
HBsAb positive rate was highest 64.8% (59/91) among patients born between 1985 and 1989. 
However, HBsAb positive rate was the lowest 28.6% (2/7) among patients born between 1995 
and 1999 despite the rate of hepatitis B vaccination history being 42.9% (3/7) (Fig. 2).
The HBsAb positive rate was found in 198 (56.7%) out of a total of 349 patients with HBV 
vaccination history. Furthermore, the HBsAb positive rate ranged from 33.3% to 66.7% in 
patients born between 1950 and 1999. HBsAg was found to be positive in four patients born 
before 1985 (1.1%) out of 349 who said they had a history of vaccination.
Next, HBsAb positivity confirmed in 635 patients were analyzed, and 198 (31.2%) of these 
patients had an HBV vaccination history. Of the remaining patients, 185 (29.1%) could not 
remember their HBV vaccination history and 252 (39.7%) stated that they had never been 
vaccinated. The result did not differ from the results of the whole cohort, regardless of the 
patients' memory and status of HBsAb.
After introduction of hepatitis B vaccination, a significant decline in the prevalence of 
HBsAg positivity among HIV-positive patients was observed in our study. This result was 
similar to Taiwan HIV study which showed declined prevalence of HBsAg positivity from 
16% to 4% after introduction of universal HBV vaccination in 1986.7 However, Korea still 
has a higher HBV prevalence rate than some other countries. Until now, the estimated 
prevalence was approximately 3% in 2016.4 The prevalence of HIV-HBV co-infection was 
5.2% in our study, which showed a higher prevalence of HBV infection in HIV patients than 
in the general population. This is consistent with other previous studies.5,8,9 This may be 
caused by similarities in routes of transmission and risk factors between HBV and HIV,10-12 
or lower incidences of spontaneous loss of HBsAg because of HIV-induced impairment of 
host innate and adaptive immunity.13 Given that most HIV infections in Korea are caused 
by sexual contact (96.8%) and that the vaccination rate for hepatitis B in Korean children is 
high, it is estimated that the chance of infection through sexual contact has increased, while 
the chance of infection by vertical infection has decreased.14 Currently, more than 1,000 new 
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Fig. 2. Decreasing human immunodeficiency virus/hepatitis B virus co-infection incidence rate according to the 
birth year in 5-year intervals. 
HBsAg = hepatitis B virus surface antigen, HBsAb = hepatitis B virus surface antibody.
HIV infected patients are identified in Korea every year. HBV transmission may still occur in 
unvaccinated or uninfected adults and can lead to chronicity. A retrospective study conducted 
in a west China hospital showed that the prevalence of HIV/HBV co-infection was 14.4% 
among 894 HIV-infected patients. A high prevalence of HIV/HBV co-infection was observed 
and the rate for HIV-infected patients who were effectively vaccinated against HBV was fewer 
than 10%.15 Hepatitis B vaccination is consider with priority for people living with HIV.
However, despite the NIPs, adult HBsAb positive rate was reported to be 70.2% in Korean 
general population.16 Our study identified that the HIV population has lower HBsAb 
positive rates compared with general population. The HBsAb positive rate was only 56.7% 
among those known to have been vaccinated against HBV. It is assumed that there are more 
possibilities for transmission and infection by hepatitis B in the HIV population.
In our study, HBsAb positive rate of young HIV patients under 30 years old was identified 
55.2% (37/67). A previous study conducted in Korea showed that HBsAb did not persist 
as protective titer despite complete HBV vaccination.6 The efficacy of vaccines may have a 
waning effect in Korea not only in general population but also in HIV patients. This would 
be a serious cause for concern among young HIV patients. A study conducted in Hong 
Kong indicated that decreased HBsAg carriage could be associated simultaneously with 
decreased seroprotection; thus, the former neonatal vaccination should not be considered 
as evidence of adequate seroprotection.17 Several studies showed that the HBsAb titer below 
the protective level after HBV vaccination could have protective effect against HBV infection 
because of anamnestic effect of HBsAb. However, it was not verified in HIV patients so called 
hyporesponders, eliciting the necessity of booster vaccination after adulthood.18,19 Vaccine-
induced immunity should not be taken for granted from the period of adolescence onwards 
especially in HIV patients. Appropriate immunization of hepatitis B may be needed to prevent 
new HBV infections.20
For HIV patients, the effect of vaccination may differ according to immunity. Factors 
associated with impaired HBV vaccine response include older age, uncontrolled HIV 
replication, and low nadir CD4+ cell counts.21 We believe that appropriate vaccination 
policies are needed especially in HIV patients with these characteristics. National health 
plans should provide specific planning for HIV patients.
Our study has some limitations. First, because of the unfilled and missing data, we could 
not identify patients who have recovered from past HBV infections. Second, we could not 
distinguish between patients being infected with HBV prior to HIV infection, and whether 
they were infected by horizontal transmission sharing a same path with HIV. Third, since 
1995, only seven patients were identified with HIV/HBV co-infection. This very small number 
of patients could have introduced a bias in our results.
In conclusion, our findings showed that the national HBV vaccination programs were 
effective in decreasing the HBV co-infection rate in HIV population. However, the HIV-HBV 
co-infection rate is still high and the HBsAb positive rate is low in Korea. Further evidences 
supporting efficacy of booster immunization for HBsAb negative HIV patients are required 
and as hepatitis B vaccine does not always provide life-long protection, efforts should be made 
to increase HBsAb positive rates among HIV patients to prevent horizontal transmission.
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